Ariad Pharmaceutical (NASDAQ: ARIA) had its target price cut by William Blair from $28.00 to $27.00 in a report released on Wednesday.

A number of other analysts have also recently weighed in on ARIA. Analysts at Jefferies Group raised their price target on shares of Ariad Pharmaceutical from $23.00 to $25.00 in a research note to investors on Tuesday. They now have a buy rating on the stock. Separately, analysts at Barclays Capital cut their price target on shares of Ariad Pharmaceutical from $30.00 to $29.00 in a research note to investors on Tuesday. They now have an overweight rating on the stock. Finally, analysts at Stifel Nicolaus cut their price target on shares of Ariad Pharmaceutical from $27.00 to $26.00 in a research note to investors on Thursday, February 14th. They now have a buy rating on the stock.

Eighteen research analysts have rated the stock with a buy rating, and two have issued a hold rating to the stock. The stock has a consensus rating of buy and a consensus price target of $28.18.

Shares of Ariad Pharmaceutical opened at 21.03 on Wednesday. Ariad Pharmaceutical has a 52 week low of $13.92 and a 52 week high of $25.40. The stock’s 50-day moving average is currently $20.22. The company’s market cap is $3.505 billion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.